While these studies suggested that increased methylation of OPRM1 is associated with more severe NAS, Camerota et al. (2022) hypothesized that pharmacotherapy for NAS would result in decreased DNA methylation and improvements in neonatal neurobehavior. This evidence concerns the gene OPRM1 and neonatal abstinence syndrome.